Search results for: hospital

IL-1-Beta Blockade May Slow OA Progression

Reuters Staff | August 4, 2020

NEW YORK (Reuters Health)—Interleukin (IL) 1 beta is a key player in the osteoarthritis (OA) inflammatory process and inhibiting it may help slow the disease process, according to an exploratory analysis of data from the CANTOS trial.1 CANTOS participants who were treated with the IL-1-beta inhibitor canakinumab had a significantly lower rate of total hip…

Study Compares Ixekizumab with Ustekinumab for the Treatment of Nail Psoriasis

Michele B. Kaufman, PharmD, BCGP | August 4, 2020

In a head-to-head study, ixekizumab was a more effective treatment for nail psoriasis than ustekinumab and resulted in greater skin clearance for patients with plaque psoriasis…

Tocilizumab Fails Late-Stage Trial for COVID-19

John Revill | July 29, 2020

ZURICH (Reuters)—Roche’s attempt to retool its rheumatoid arthritis drug Actemra/RoActemra (tocilizumab) to treat patients hospitalized with severe COVID-19-related pneumonia has failed in a late-stage trial, the Swiss company said on July 29. Roche launched the 452-patient trial in March as it joined other pharmaceutical companies seeking to re-purpose existing medicines to fight the pandemic. The…

Denosumab Dosing Delays Tied to Increased Fracture Risk

Megan Brooks | July 27, 2020

NEW YORK (Reuters Health)—Denosumab injection delays of more than four months are associated with an increased risk of fracture compared with on-time injections, especially at the spine, new research indicates. “This study suggests the importance of timely denosumab administration when used for long-term osteoporosis management,” the researchers write in Annals of Internal Medicine.1 “When starting…

How to Empower Lupus Patients Through Social Media & Online Resources

Carina Stanton | July 27, 2020

Social media connections, such as LupusChat and online resources from the ACR’s Lupus Initiative, are providing safe spaces and support for lupus patients during the COVID-19 pandemic…

ACR Updates COVID-19 Clinical Guidance for Adult Patients

From the College | July 21, 2020

Note: This article was updated July 21 to add recommendations on restarting biologics following COVID-19. On April 29, the ACR released Guidance for the Management of Adult Patients with Rheumatic Disease During the COVID‐19 Pandemic and later updated the guidance for publication in Arthritis & Rheumatology. The recommendations address various treatment options and provide general…

RheumPAC Supports Rheumatology Through the Pandemic

Kurt Ullman | July 17, 2020

With usual in-person fundraisers and meetings not possible during the pandemic, RheumPAC is finding creative ways to keep advocating for influential legislation and ensure rheumatology’s voice is heard in Washington, D.C.

COVID-19: Practical Tips for Practices

Susan Bernstein | July 17, 2020

The ACR’s July 13 online town hall, “COVID-19 Guidance for Community Practices,” covered telehealth, safe clinic reopening and Department of Health & Human Services loans.

Rheum After 5: Dr. Veena Patel Combines Her Love of Medicine & Art

Carol Patton | July 15, 2020

As a young child growing up in Oxford, Ohio, Veena Patel, MD, demonstrated a talent for arts and crafts. At age 7, she painted a portrait of her father, now a retired mechanical engineer, which he still proudly admires. Dr. Patel, an assistant rheumatology professor at Dell Medical School—the graduate medical school of the University…

Case Report: Does She Have a Fungal Infection or Autoimmune Disease?

Sarah Dill, MD, & Duane Pearson, MD | July 15, 2020

A 61-year-old Caucasian woman with a history of seropositive rheumatoid arthritis (RA) was hospitalized for a several-month history of progressively worsening left ankle pain and swelling. She had been unable to bear weight on her left leg for several days and did not notice improvement in symptoms with 20 mg of prednisone daily, which she…